Want to see CPIX full AI Analyst Report?
Cumberland Pharmaceuticals (CPIX) AI Stock Analysis
Top Page
Cumberland Pharmaceuticals
(NASDAQ:CPIX)
The score is held down primarily by weak financial performance (sharp TTM revenue contraction, large losses, and renewed cash burn) and bearish technicals (below major moving averages with negative MACD). Valuation is mixed—very high dividend yield supports the score but is paired with losses (negative P/E) and cash-flow pressure. Corporate events provide some upside from ifetroban regulatory and trial progress, though with meaningful regulatory and timeline risk.
Cumberland Pharmaceuticals Key Performance Indicators (KPIs)
Net Revenue by ProductBreaks down sales by individual drug or product, showing which items drive total revenue and how dependent the company is on a few offerings. For Cumberland Pharmaceuticals, product-level revenue highlights concentration risk, the effect of pricing or reimbursement shifts, and whether new launches or partnerships are expanding the business and supporting sustainable growth.
Revenue is concentrated in a few brands—Sancuso, Vibativ and the recent Talicia ramp supply most of the commercial momentum while Kristalose has softened and several smaller SKUs are lumpy or one‑time. Management’s Apotex sale effectively monetizes that concentrated, volatile commercial base into cash and lower ongoing operating expenses, shifting Cumberland from a marketed‑product company to a development‑focused, asset‑light entity where future value will hinge on ifetroban milestones and successful transaction execution/timing.
The FlyCumberland Pharmaceuticals (CPIX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $70.27M
- Dividend Yield
- 29.55%
- Average Volume (3M)
- 83.53K
- Price to Earnings (P/E)
- -6.6
- Beta (1Y)
- 0.15
- Revenue Growth
- -25.68%
- EPS Growth
- -244.92%
- Country
- US
- Employees
- 88
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Cumberland Pharmaceuticals Business Overview & Revenue Model
Company Description
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastro...
How the Company Makes Money
Cumberland makes money primarily by selling its branded prescription pharmaceuticals. Revenue is generated when hospitals, clinics, and other healthcare providers purchase its products through pharmaceutical wholesalers and distributors, with end-dem...
Cumberland Pharmaceuticals Earnings Call Summary
The call highlights meaningful strategic progress: a transformational $100M acquisition agreement that unlocks near-term value, regulatory wins (expanded Caldolor label and facility clearance), commercialization progress (Talicia promotion, Vibativ China shipment) and an encouraging development pipeline (ifetroban with Fast Track and robust safety data). These positives are tempered by a modest Q1 revenue base, a GAAP net loss (~$3.3M) and limited cash on hand until the transaction closes, plus the company’s deliberate pivot away from pursuing double-digit revenue growth in 2026. On balance, the call emphasizes value realization and a clear strategic plan to focus on development, with the transaction expected to materially strengthen the balance sheet and reduce operating expense burden—leading to a favorable overall tone.
Q1-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that, given the announced strategic transaction with Apotex, Cumberland is no longer targeting double‑digit revenue growth for 2026 and expects materially lower operating expenses after closing because Apotex will assume sales, marketing, medical, manufacturing and FDA fees; at closing Cumberland expects $100 million cash (subject to shareholder approval), $9 million for inventory, ongoing monthly transition service fees and future milestone payments. For context, Q1 combined brand revenue was $9.1 million (Kristalose $1.0M; Sancuso $2.9M; Vibativ $2.1M; Caldolor $1.0M; Talicia $1.9M), total operating expenses were $12.3M, net loss was about $3.3M, adjusted loss was $1.9M or $0.13 per share, cash flow from operations was $0.387M, total assets were $71M (cash $11M), liabilities $49.7M (including $5M credit facility) and shareholders’ equity $21.6M. Management also said 2026 clinical spending is expected to remain essentially unchanged, noted over $53M of tax net operating losses versus a $30M tax basis in the assets (supporting modest taxes on the deal), and highlighted pipeline progress (ifetroban dosed in ~1,400 subjects, Fast Track/orphan/rare pediatric designations) and product milestones such as FDA‑expanded Caldolor labeling and a Vaprisol relaunch expected this year.
Cumberland Pharmaceuticals Financial Statement Overview
Summary
Overall fundamentals are pressured: TTM revenue fell sharply (-46.8%) with a large net loss (net margin -49.0%) and negative operating results. Cash flow also deteriorated, with negative operating cash flow (-$2.4M) and negative free cash flow (-$2.5M). The balance sheet is a partial offset with manageable leverage (debt-to-equity 0.27), but ongoing losses and cash burn increase execution and financing risk.
Income Statement
24NegativeBalance Sheet
56NeutralCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.27M | 44.52M | 37.87M | 39.55M | 42.01M | 35.99M |
| Gross Profit | 26.07M | 37.85M | 31.28M | 33.49M | 32.89M | 27.17M |
| EBITDA | -5.08M | 2.96M | 182.42K | 153.32K | 332.92K | -857.83K |
| Net Income | -10.61M | -2.84M | -6.48M | -6.28M | -5.57M | -3.51M |
Balance Sheet | ||||||
| Total Assets | 62.88M | 76.82M | 75.58M | 81.78M | 92.93M | 84.46M |
| Cash, Cash Equivalents and Short-Term Investments | 3.86M | 11.44M | 17.96M | 18.32M | 19.76M | 27.04M |
| Total Debt | 4.71M | 10.18M | 20.57M | 18.43M | 20.96M | 16.06M |
| Total Liabilities | 45.77M | 52.28M | 53.04M | 52.52M | 56.95M | 41.86M |
| Stockholders Equity | 17.44M | 24.88M | 22.85M | 29.60M | 36.27M | 42.81M |
Cash Flow | ||||||
| Free Cash Flow | -1.11M | 4.83M | -791.90K | 5.64M | 6.38M | 5.99M |
| Operating Cash Flow | 745.97K | 4.93M | -612.19K | 6.09M | 8.45M | 6.34M |
| Investing Cash Flow | -5.75M | -4.71M | 57.84K | -105.69K | -13.67M | -501.89K |
| Financing Cash Flow | -7.22M | -6.75M | 196.90K | -7.42M | -2.06M | -3.55M |
Cumberland Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPIX, the sentiment is Negative. The current price of 4.69 is below the 20-day moving average (MA) of 6.73, below the 50-day MA of 7.12, and below the 200-day MA of 4.80, indicating a bearish trend. The MACD of -0.61 indicates Positive momentum. The RSI at 35.36 is Neutral, neither overbought nor oversold. The STOCH value of 9.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CPIX.
Cumberland Pharmaceuticals Risk Analysis
Cumberland Pharmaceuticals disclosed 1 risk factors in its most recent earnings report. Cumberland Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksCumberland Pharmaceuticals Peers Comparison
Overall Rating
ANIP75Outperform
ETON74Outperform
AMPH68Neutral
COLL64Neutral
PCRX62Neutral- CPIX47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ANIP | 75Outperform | $1.65B | 14.91 | 19.19% | ― | 30.90% | ― |
| ETON | 74Outperform | $1.49B | 112.22 | 40.13% | ― | 81.49% | ― |
| AMPH | 68Neutral | $1.18B | 15.93 | 10.11% | ― | 1.02% | -38.09% |
| COLL | 64Neutral | $774.82M | 15.55 | 15.96% | ― | 14.31% | 34.35% |
| PCRX | 62Neutral | $1.45B | 103.35 | 2.13% | ― | 5.71% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CPIX | 47Neutral | $70.27M | -6.56 | -47.10% | 29.55% | -25.68% | -244.92% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CPIX | Cumberland Pharmaceuticals Inc. | 4.69 | 2.55 | 119.16% | |
| PCRX | Pacira | 36.39 | 14.20 | 63.99% | |
| ANIP | Ani Pharmaceuticals | 72.00 | -22.06 | -23.45% | |
| AMPH | Amphastar Pharmaceuticals Inc | 27.72 | 2.42 | 9.57% | |
| COLL | Collegium Pharmaceutical Inc. | 23.80 | -12.30 | -34.07% | |
| ETON | Eton Pharmaceuticals | 52.18 | 34.22 | 190.53% |
Cumberland Pharmaceuticals Corporate Events
Cumberland to Submit NDA for Ifetroban DMD Therapy
PositiveOn October 26, 2026, Cumberland Pharmaceuticals announced plans to submit a New Drug Application to the U.S. Food and Drug Administration for ifetroban as a treatment for cardiomyopathy associated with Duchenne muscular dystrophy, following a series...
Cumberland Reports Positive Phase 2a Ifetroban Safety Results
PositiveOn October 23, 2026, Cumberland Pharmaceuticals Inc. reported top-line results from its Phase 2a ASSIST-SSc clinical trial of oral ifetroban in patients with systemic sclerosis, a rare autoimmune disease. The data indicated that ifetroban was safe an...
Cumberland Pharmaceuticals Updates Ifetroban DMD Trial Timeline
NegativeOn June 26, 2026, Cumberland Pharmaceuticals presented data from its Phase 2 FIGHT DMD trial of ifetroban, an oral therapy for Duchenne muscular dystrophy–related heart disease, at the Parent Project Muscular Dystrophy conference in Orlando, Fl...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026